This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirby, J. T. Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Kirby, J. T. Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2004, p. 445-448, Vol. 42, No. 1
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.1.445-448.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001)

The Jones Group/JMI Laboratories, North Liberty, Iowa,¹ Federal University of São Paulo, São Paulo, Brazil,² University of Bristol, Bristol, United Kingdom,³ Tufts University School of Medicine, Boston, Massachusetts⁴

Received 21 July 2003/ Returned for modification 1 September 2003/ Accepted 10 October 2003

Limited data are available on Chryseobacterium spp. leading to an evaluation of the patient demographics and susceptibility patterns for Chryseobacterium spp. collected in the first 5 years of the SENTRY Antimicrobial Surveillance Program (1997 to 2001). Fifty isolates (24 Chryseobacterium meningosepticum, 20 Chryseobacterium indologenes, two Chryseobacterium gleum, and 4 Chryseobacterium spp. isolates) were collected. The highest Chryseobacterium prevalence was detected among the elderly. The most active antimicrobials were the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the isolates are inhibited [MIC₉₀] of 1 µg/ml and 98.0% susceptibility) followed by rifampin (MIC₉₀, 2 µg/ml and 85.7% susceptibility). Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity; vancomycin showed poor potency.

This article has been cited by other articles:

• Tuon, F. F., Campos, L., Duboc de Almeida, G., Gryschek, R. C. (2007). Chryseobacterium meningosepticum as a cause of cellulitis and sepsis in an immunocompetent patient. J Med Microbiol 56: 1116-1117 [Abstract] [Full Text]  
• Ozkalay, N., Anil, M., Agus, N., Helvaci, M., Sirti, S. (2006). Community-Acquired Meningitis and Sepsis Caused by Chryseobacterium meningosepticum in a Patient Diagnosed with Thalassemia Major.. J. Clin. Microbiol. 44: 3037-3039 [Abstract] [Full Text]  
• Chen, G.-X., Zhang, R., Zhou, H. W. (2006). Heterogeneity of metallo-{beta}-lactamases in clinical isolates of Chryseobacterium meningosepticum from Hangzhou, China. J Antimicrob Chemother 57: 750-752 [Abstract] [Full Text]  
• Lee, C.-C., Chen, P.-L., Wang, L.-R., Lee, H.-C., Chang, C.-M., Lee, N.-Y., Wu, C.-J., Shih, H.-I, Ko, W.-C. (2006). Fatal Case of Community-Acquired Bacteremia and Necrotizing Fasciitis Caused by Chryseobacterium meningosepticum: Case Report and Review of the Literature.. J. Clin. Microbiol. 44: 1181-1183 [Abstract] [Full Text]  
• Cascio, A., Stassi, G., Costa, G. B, Crisafulli, G., Rulli, I., Ruggeri, C., Iaria, C. (2005). Chryseobacterium indologenes bacteraemia in a diabetic child. J Med Microbiol 54: 677-680 [Abstract] [Full Text]  
• Christakis, G. B., Perlorentzou, S. P., Chalkiopoulou, I., Athanasiou, A., Legakis, N. J. (2005). Chryseobacterium indologenes Non-Catheter-Related Bacteremia in a Patient with a Solid Tumor. J. Clin. Microbiol. 43: 2021-2023 [Abstract] [Full Text]